Determining Patterns In Trial Experiences of Parkinson's Disease Patients

Power Life Sciences Inc. (Industry)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

Historically, participation in clinical studies is highly skewed towards particular demographic groups of people.

This study will invite several participants to gather a wide range of information on clinical trial experiences for Parkinson's Disease patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of Parkinson's Disease.

The data collected from this study will help improve future outcomes for all Parkinson's Disease patients as well as those in under-represented demographic groups.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Time Perspective:
    Official Title:
    An In Depth Study Examining Patterns in the Clinical Trial Experiences of Parkinson's Disease Patients
    Anticipated Study Start Date :
    Feb 5, 2023
    Anticipated Primary Completion Date :
    Feb 5, 2024
    Anticipated Study Completion Date :
    Feb 5, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients who decide to enroll in an Parkinson's Disease clinical trial [3 months]

    2. Rate of patients who remain in Parkinson's Disease clinical trial to trial completion [12 months]

    Eligibility Criteria


    Ages Eligible for Study:
    50 Years to 80 Years
    Sexes Eligible for Study:
    Inclusion Criteria:
    • Patient plans to participate in an interventional clinical trial for the condition of Parkinson's Disease

    • Patient has been diagnosed with a type of Parkinson's Disease

    • Patient is at least 50 to 80 years of age

    • Patient has access to a home internet connection in order to provide regular updates through the course of the study

    Exclusion Criteria:
    • Patient has an ECOG score of 4 or higher

    • Patient is not able to provide consistent digital updates as per study requirements

    • Patient does not complete or agree to terms outlined in the Informed Consent Form

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • Power Life Sciences Inc.


    • Study Director: Michael B Gill, Power Life Sciences Inc.

    Study Documents (Full-Text)

    More Information


    Responsible Party:
    Power Life Sciences Inc. Identifier:
    Other Study ID Numbers:
    • 87526739
    First Posted:
    Jan 17, 2023
    Last Update Posted:
    Jan 17, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by Power Life Sciences Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 17, 2023